Additional Positive Results for Omisirge(R) in Treating Severe Aplastic Anemia Presented at ASH
New data presented at the 2025 ASH demonstrates 94% disease free and overall survival rate Omisirge approved by FDA as First Cell Therapy to Treat Severe Aplastic Anemia Key Highlights…
